Skip to main content
Peter Roy-Byrne, MD, Psychiatry, Seattle, WA

PeterPRoy-ByrneMD

Psychiatry Seattle, WA

Psychosomatic Medicine

Professor in the Department of Psychiatry and Behavioral Sciences at the University of Washington.

Dr. Roy-Byrne is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Roy-Byrne's full profile

Already have an account?

  • Office

    Psychiatric Medicine Associates
    1505 Westlake Ave N suite 920
    Seattle, WA 98104
    Phone+1 206-386-3103
    Fax+1 206-386-3123
  • Is this information wrong?

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterResidency, Psychiatry, 1982 - 1985
  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Psychiatry, 1979 - 1982
  • Steward Carney Hospital
    Steward Carney HospitalInternship, Internal Medicine, 1978 - 1979
  • Tufts University School of Medicine
    Tufts University School of MedicineClass of 1978

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1979 - Present
  • WA State Medical License
    WA State Medical License 1986 - 2025
  • MD State Medical License
    MD State Medical License 1982 - 1987
  • American Board of Psychiatry and Neurology Psychiatry

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2002-2014
  • Women's Health Castle Connolly, 2008

Clinical Trials

Publications & Presentations

PubMed

Other

Press Mentions

  • Novel Antidepressant Reduces Depression Symptoms in 2 Weeks
    Novel Antidepressant Reduces Depression Symptoms in 2 WeeksSeptember 4th, 2019
  • Amphetamine Tied to Higher Psychosis Risk in Young People with ADHD
    Amphetamine Tied to Higher Psychosis Risk in Young People with ADHDMarch 21st, 2019
  • FDA Panel Recommends Approving Nasal Spray for Resistant Depression
    FDA Panel Recommends Approving Nasal Spray for Resistant DepressionFebruary 14th, 2019
  • Join now to see all

Grant Support

  • Brief Intervention In Primary Care For Problem Drug Use And AbuseNational Institute On Drug Abuse2008–2011
  • Improving Mental Health Care In Safety NET Medical SettingsNational Institute Of Mental Health2010
  • Calm: Improving Primary Care OutcomesNational Institute Of Mental Health2005–2009
  • Treating Anxiety In Public Sector Medical SettingsNational Institute Of Mental Health2003–2007
  • Improving Care For Panic Disorder In Primary CareNational Institute Of Mental Health1999–2002
  • Benzodiazepine Sensitivity In Human AnxietyNational Institute Of Mental Health1992–1993
  • Benzodiazepine Sensitivity In Panic &General AnxietyNational Institute Of Mental Health1988–1990